The merger between Skyepharma and Vectura has created a global leader in the development of therapeutic respiratory products, with strong global partners and broad development capability across multiple formulation platforms, drug classes and delivery forms. In this report we outline the company’s three strongest valuation drivers, a selection of high-potential development programmes and the financial outlook for the enlarged group. We forecast continued strong growth in royalty income and suppl ....
21 Jun 2016
N+1 Singer - Vectura Group - A leader in respiratory product development
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Vectura Group - A leader in respiratory product development
- Published:
21 Jun 2016 -
Author:
Dr Jens Lindqvist -
Pages:
22
The merger between Skyepharma and Vectura has created a global leader in the development of therapeutic respiratory products, with strong global partners and broad development capability across multiple formulation platforms, drug classes and delivery forms. In this report we outline the company’s three strongest valuation drivers, a selection of high-potential development programmes and the financial outlook for the enlarged group. We forecast continued strong growth in royalty income and suppl ....